As a global corporate citizen, BioMarin strives to operate in ways that protect the environment and contribute to the health of our employees and communities. We have a long history of reducing our environmental footprint through the comprehensive efforts here.
We have demonstrated our commitment to this by:
We have contributed to conservation efforts by:
BioMarin manages our operations and global supply chain in compliance with applicable export, import and trade compliance laws, including those related to trade embargoes and economic sanctions, export control, boycott, cargo security, import classification and valuation, origin, marking and free trade agreements
At BioMarin, we expect our suppliers to operate according to the same ethical and environmentally sustainable principles we hold for our business. Our Supplier Code of Conduct highlights our expectations that suppliers enforce safe working conditions, treat their workers with respect and dignity, and utilize sound and environmentally sustainable business practices.
We are committed to supporting fair and just labor practices by keeping our global supply chain and operations free of human trafficking, human slavery and forced labor. For more information or to view our statement regarding human trafficking, see BioMarin’s California Transparency in Supply Chains and UK Modern Slavery Act Statement.
We comply with all regulations and laws pertaining to reporting on adverse events (AE) and special situation events (SSE). Any BioMarin employee who becomes aware of an AE or SSE must forward certain enumerated information within one business day to the Pharmacovigilance department.
BioMarin is committed to the safety of patients and meeting all GxP regulations and policies.
BioMarin is committed to fair competition as a matter of corporate conduct. We abide by all laws that apply to marketing activities, including prohibiting:
BioMarin is committed to understanding the impact of our business practices on the environment and managing our global emissions footprint. We further recognize the importance of understanding our climate-related risks and acknowledging our stakeholders’ interests in our plans to continue ensuring we prioritize minimizing our impact on the environment.
Our campuses consist of multiple manufacturing facilities that produce biologic and gene therapies and perform important pilot scale work, in addition to laboratories, warehouses and office space supporting our clinical development and commercial initiatives.
For 2020, activities at the two campuses generated the above GHG emissions
BioMarin developed and implemented a standard for the collection and verification of GHG data that aligns reporting of this information with the Principles for Effective Disclosure section of the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and the GHG Protocol.
BioMarin has also begun to assess the most impactful and cost-efficient mitigation strategies to minimize our carbon footprint.
1 Data covers all buildings within our operational control at our Northern California and Shanbally campuses. Sources of Scope 1 emissions from our campuses include combustion of fuels by stationary equipment, releases of refrigerants and laboratory use of chemicals.
2 The location-based figure we have reported for our Scope 2 emissions is based on the amount of electricity purchased and the average emissions intensity of the grids on which our energy consumption occurs. It does not account for the fact that we purchase electricity for all of our campuses that is generated from renewable sources like wind and solar.
3 Emissions associated with our Northern California campuses were calculated in accordance with the GHG Protocol and methodologies at US 40 CFR 98 and 17 CCR 95000 et seq., and by utilizing EPA eGRID emission factors.
4 Emissions associated with our Shanbally campus were calculated in accordance with the GHG Protocol and by utilizing common conversion factors for energy use in Ireland (https://www.seai.ie/data-and-insights/seai-statistics/conversion-factors/).
5 2020 figures have been updated to include all of our Northern California campuses within our operational control. Previously published figures only included emissions from our Novato and Shanbally manufacturing campuses.
6 Total Scope 1 + 2 GHG emissions have stayed relatively flat despite an increase in manufacturing capacity at our Shanbally campus. GHG reduction initiatives, such as conversion to LED lighting, have balanced increases in emissions from new bioreactors and packaging suites, in addition to a new fill finish facility and a cold chain storage building.